DK1833965T3 - Fremgangsmåde til visning af ribosom eller mrna med udvælgelse for øget stabilitet for proteinet - Google Patents
Fremgangsmåde til visning af ribosom eller mrna med udvælgelse for øget stabilitet for proteinetInfo
- Publication number
- DK1833965T3 DK1833965T3 DK06700177.6T DK06700177T DK1833965T3 DK 1833965 T3 DK1833965 T3 DK 1833965T3 DK 06700177 T DK06700177 T DK 06700177T DK 1833965 T3 DK1833965 T3 DK 1833965T3
- Authority
- DK
- Denmark
- Prior art keywords
- selection
- ribosom
- mrna
- displaying
- stability
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64220905P | 2005-01-05 | 2005-01-05 | |
| GBGB0500099.7A GB0500099D0 (en) | 2005-01-05 | 2005-01-05 | Methods and means relating to protein variants |
| PCT/GB2006/000002 WO2006072773A1 (en) | 2005-01-05 | 2006-01-05 | Ribosome display or mrna display method with selection for increased stability of the protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1833965T3 true DK1833965T3 (da) | 2012-03-26 |
Family
ID=34179181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06700177.6T DK1833965T3 (da) | 2005-01-05 | 2006-01-05 | Fremgangsmåde til visning af ribosom eller mrna med udvælgelse for øget stabilitet for proteinet |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8288123B2 (da) |
| EP (1) | EP1833965B1 (da) |
| JP (1) | JP5154947B2 (da) |
| CN (1) | CN101180393A (da) |
| AT (1) | ATE538199T1 (da) |
| AU (1) | AU2006204424B2 (da) |
| CA (1) | CA2593151C (da) |
| DK (1) | DK1833965T3 (da) |
| ES (1) | ES2379189T3 (da) |
| GB (2) | GB0500099D0 (da) |
| WO (1) | WO2006072773A1 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60332358D1 (de) | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| GB0500099D0 (en) * | 2005-01-05 | 2005-02-09 | Cambridge Antibody Tech | Methods and means relating to protein variants |
| KR101248252B1 (ko) * | 2006-11-28 | 2013-03-27 | 한올바이오파마주식회사 | 변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도 |
| EP1930342B1 (en) * | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold used as scaffold for engineering new specific binders |
| EP2297197B1 (en) * | 2008-05-29 | 2012-03-07 | HanAll Biopharma Co., Ltd. | Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof |
| EP2342562B1 (en) * | 2008-09-30 | 2013-09-18 | AbbVie Inc. | Improved method of rna display |
| SG173747A1 (en) * | 2009-02-18 | 2011-09-29 | Univ Wayne State | Method for identifying a subpopulation of mammalian cells with distinctive ribosome translation profiles |
| MX2013007067A (es) | 2010-12-20 | 2013-11-01 | Medimmune Ltd | Anticuerpos anti-il-18 y sus usos. |
| CN103130893A (zh) * | 2011-12-05 | 2013-06-05 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | 己烯雌酚单链抗体筛选方法及其用途 |
| RU2689674C2 (ru) | 2012-10-15 | 2019-05-28 | Медиммьюн Лимитед | Антитела к бета-амилоиду |
| US10421958B2 (en) | 2014-02-05 | 2019-09-24 | Molecular Templates, Inc. | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity |
| WO2016187068A1 (en) | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| WO2018005283A1 (en) * | 2016-06-27 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Methods for measuring rna translation rates |
| US11015188B2 (en) | 2017-11-20 | 2021-05-25 | NantBio Inc. | MRNA display antibody library and methods |
| US11034951B2 (en) | 2017-11-20 | 2021-06-15 | Nantbio, Inc. | mRNA display antibody library and methods |
| EP3853252A1 (en) | 2018-09-18 | 2021-07-28 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
| WO2020159524A1 (en) * | 2019-01-31 | 2020-08-06 | Nantbio, Inc. | Mrna display antibody library and methods |
| WO2020180712A1 (en) | 2019-03-01 | 2020-09-10 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1737888A2 (en) * | 2004-04-23 | 2007-01-03 | Cambridge Antibody Technology LTD | Erythropoietin protein variants |
| GB0500099D0 (en) * | 2005-01-05 | 2005-02-09 | Cambridge Antibody Tech | Methods and means relating to protein variants |
-
2005
- 2005-01-05 GB GBGB0500099.7A patent/GB0500099D0/en not_active Ceased
-
2006
- 2006-01-05 EP EP06700177A patent/EP1833965B1/en active Active
- 2006-01-05 DK DK06700177.6T patent/DK1833965T3/da active
- 2006-01-05 AT AT06700177T patent/ATE538199T1/de active
- 2006-01-05 CA CA2593151A patent/CA2593151C/en active Active
- 2006-01-05 JP JP2007548905A patent/JP5154947B2/ja active Active
- 2006-01-05 US US11/326,710 patent/US8288123B2/en active Active
- 2006-01-05 US US11/813,199 patent/US20070298430A1/en not_active Abandoned
- 2006-01-05 AU AU2006204424A patent/AU2006204424B2/en active Active
- 2006-01-05 GB GB0600147A patent/GB2422606B/en active Active
- 2006-01-05 CN CNA2006800072126A patent/CN101180393A/zh active Pending
- 2006-01-05 WO PCT/GB2006/000002 patent/WO2006072773A1/en active Application Filing
- 2006-01-05 ES ES06700177T patent/ES2379189T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| GB2422606B (en) | 2007-02-21 |
| EP1833965A1 (en) | 2007-09-19 |
| US20070298430A1 (en) | 2007-12-27 |
| GB0600147D0 (en) | 2006-02-15 |
| AU2006204424A1 (en) | 2006-07-13 |
| GB0500099D0 (en) | 2005-02-09 |
| US8288123B2 (en) | 2012-10-16 |
| GB2422606A (en) | 2006-08-02 |
| AU2006204424B2 (en) | 2011-09-08 |
| JP2008526191A (ja) | 2008-07-24 |
| WO2006072773A1 (en) | 2006-07-13 |
| JP5154947B2 (ja) | 2013-02-27 |
| ATE538199T1 (de) | 2012-01-15 |
| ES2379189T3 (es) | 2012-04-23 |
| EP1833965B1 (en) | 2011-12-21 |
| CN101180393A (zh) | 2008-05-14 |
| US20060183200A1 (en) | 2006-08-17 |
| CA2593151C (en) | 2016-03-15 |
| CA2593151A1 (en) | 2006-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1833965T3 (da) | Fremgangsmåde til visning af ribosom eller mrna med udvælgelse for øget stabilitet for proteinet | |
| AR062069A1 (es) | Replegado de proteinas recombinantes | |
| DK2089343T3 (da) | Click-kemi til fremstilling af reportermolekyler | |
| DK2450439T3 (da) | Cellulosenedbrydende enzymer, nucleinsyrer, der koder for dem, og fremgangsmåder til at fremstille og benytte dem | |
| CO6470854A2 (es) | Variantes de celulasa con expresión, actividad y/o estabilidad mejoradas, y uso de las mismas | |
| NO20082170L (no) | Forbedret testosterongel og fremgangsmate til anvendelse | |
| DK2126586T3 (da) | Direkte bestemmelse af vitamin D i serum eller plasma | |
| DK1737974T3 (da) | Fremgangsmåder til identifikation af proteiner med stivelsesphosphorylerende enzymatisk aktivitet | |
| DE602006011343D1 (de) | Materialschicht zur aufnahme von überschüssigem klebstoff | |
| WO2009149956A3 (en) | Fusion protein and use thereof | |
| BR112017016897A2 (pt) | cepas fúngicas e métodos de uso | |
| BRPI0822219A2 (pt) | Ácidos nucléicos de aminotransferase e oxidoreductase e polipeptídeos e métodos de uso. | |
| NO20055686L (no) | Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav. | |
| BRPI0819649A2 (pt) | método, organismo geneticamente modificado, e, célula de levedura recinbinante | |
| BRPI0921995A2 (pt) | processo de deslocamento de gás para água , e, uso de um adsorvente. | |
| DE602005019156D1 (de) | Verfahren zur auswertung von ribonukleotidsequenzen | |
| TW200739068A (en) | Composite chromatography column | |
| DE602008006254D1 (de) | Doppel-oligonukleotid-nukleinsäurenachweisverfahren | |
| BRPI0913178A2 (pt) | Método para produzir um hidrolisado de caseína, hidrolisado de caseína, e, uso de hidrolisado de caseína | |
| WO2009139601A3 (en) | Method and affinity column for purifying proteins | |
| DK1668125T3 (da) | Modificerede enzymer, fremgangsmåde til fremstilling af modificerede enzymer og anvendelser deraf | |
| WO2008034622A3 (en) | A method of detecting and/or quantifying expression of a target protein candidate in a cell, and a method of identifying a target protein of a small molecule modulator | |
| BRPI0913174A2 (pt) | Método para produzir um hidrolisado de proteína de trigo, hidrolisado de proteína de trigo, e, uso de um hidrolisado de proteína de trigo. | |
| NO20071456L (no) | Motorkontrollmodul og fremgangsmate for a bruke denne i motorsystemproduksjon | |
| WO2006079334A3 (de) | Verfahren zu nachweis und quantifizierung von proteinen unter verwendung von farbstoffen auf der basis von polymethinen |